Polyneuropathy

This research aims to evaluate the outcomes of surgically treated acute traumatic peripheral nerve injuries in the upper extremity, focusing on their long-term effects on sensory and motor functions, overall functional status, and quality of life. The study observes patients with nerve damage resulting from trauma to the nervous system, particularly injuries involving the median, ulnar, radial nerves, or combinations of these. Participants will undergo standard clinical and functional assessments to monitor the status of their nerve injuries. These assessments include evaluating motor and sensory functions and overall hand functionality without being assigned to a specific treatment. The study observes different nerve injury types such as ulnar nerve, median nerve, or combined injuries. During the study, participants will be evaluated at six months after injury using tools like the Michigan Hand Outcomes Questionnaire to assess hand function, grip strength measured by a dynamometer, Semmes-Weinstein monofilament test for sensation, and static two-point discrimination test. The study period involves regular clinical and functional evaluations to track recovery and impact on quality of life over time.

Researchers are investigating the relationship between amylin, a hormone increased in people with Type-2 diabetes, and peripheral neuropathy symptoms in patients with this condition. The study explores whether the amount of amylin in the upper limbs correlates with the severity of nerve damage symptoms. This observational study aims to better understand how diabetes-related vascular damage affects nerve function and may identify biomarkers for disease severity. Participants will provide blood samples and skin biopsies from the forearm to measure amylin deposition in blood vessels and red blood cells. The study also includes nerve conduction velocity tests and sensory assessments of pain and temperature response in the upper extremities. These tests occur at the time of sample collection and follow-up sensory testing one week later. Throughout the study, participants undergo clinical sensory exams, nerve conduction velocity testing, and pain threshold evaluations using pressure, cold, and heat stimuli. Researchers will compare amylin levels to symptom severity and nerve function. The study collects data at single time points and includes follow-up sensory testing to provide preliminary insights for larger trials. Total participation involves initial testing and follow-up assessments one week later.

The GENESIS clinical study aims to map HLA genetic variation in the Greek population and evaluate possible correlations with selected underlying diseases. It is a multicenter, prospective, non-interventional clinical study targeting 12,000 subjects over an anticipated duration of 36 months, with the goal of creating a pilot HLA map for medical research and possible clinical applications. Each subject will complete one visit at a participating site and provide demographic information, including date of birth, gender, race, ancestry, height, and weight, as well as information about smoking or vaping, alcohol consumption, arterial blood pressure, diagnosed diseases, and current treatments. Recent clinical laboratory results from up to 12 months before sample collection may also be collected when available, including blood count, metabolic, liver enzyme, and biochemical parameters. Two buccal swabs will be collected from each subject for DNA extraction and HLA genotyping analysis. Selected DNA samples will also undergo low-pass whole genome sequencing to further investigate associations between the HLA region and autoimmune diseases. After the analysis is completed, an individualized ancestry report will be securely available to study subjects if they elect to access it.

Researchers are developing a multicenter registry to collect and share data on pediatric patients who have undergone deep brain stimulation DBS for movement disorders such as dystonia, epilepsy, Tourette syndrome, and mood disorders. The study aims to improve understanding of DBS safety and effectiveness in children, as current data are limited and individual centers often have too few cases for strong research. This registry will support large-scale analyses and help refine DBS as a treatment option for hyperkinetic movement disorders in the pediatric population. The study involves gathering both retrospective and prospective clinical data from multiple pediatric centers. The registry will collect information on surgical techniques, patient outcomes, implant sites, and long-term effects of DBS. This collaborative data-sharing approach enables comprehensive evaluation of which patients benefit most from DBS and how it impacts their quality of life over time. Participants include children aged 0 to 18 years who have already received or are scheduled to receive DBS for neurological movement disorders. Data will be collected over five years to monitor safety, efficacy, and quality of life outcomes. The study does not involve treatment administration but focuses on gathering and analyzing clinical information. Parental or legal guardian consent is required for prospective participation.

This research aims to evaluate postoperative respiratory complications PORC in children with obstructive sleep apnea OSA who undergo adenotonsillectomy. It combines data from two centers University Hospital Antwerp and Heim Pal National Pediatric Institute in Hungary. The study examines how common these complications are and whether they vary according to different health conditions such as obesity, craniofacial malformations, Down syndrome, or neurological disorders that affect airway muscle tone. Data come from a retrospective analysis of electronic health records originally collected in two prospective studies. These records include children who had adenotonsillectomy for OSA, with postoperative care following a set protocol. The study looks at factors like the obstructive apnea-hypopnea index, oxygen levels during sleep studies, age at surgery, and presence of other health conditions to understand their relationship with PORC and to help develop a management plan. Participants information was collected without needing additional consent because it uses existing anonymized data. Researchers assess the prevalence of PORC within 24 hours after surgery and analyze how different factors affect this risk. This study does not involve new treatments but reviews existing data to improve postoperative care. The study includes children aged 1 to 18 years who had adenotonsillectomy for OSA, with follow-up limited to the immediate postoperative period.

Researchers are studying how muscle and brain interactions relate to neurodegenerative diseases NDGs such as Amyotrophic Lateral Sclerosis, Alzheimers Disease, and Parkinsons Disease, as well as aging. The study explores whether changes at the neuromuscular junction, where muscle and nerve communicate, contribute to these conditions. It aims to identify factors that influence brain-muscle connections and how these may predict disease progression or aging outcomes. This observational case-control study includes two groups a Good Aging group of adults aged 60 or older without muscle or neurological impairments, and a Bad Aging group with patients diagnosed with NDGs or severe acquired brain injury, some with sarcopenia or cognitive issues. Researchers will collect clinical and biological data, including biomarkers, microRNA, and extracellular vesicle analyses, to better understand the muscle-brain relationship and movement issues. Participants will undergo assessments including the Edmonton Frail Scale at the start and after six months to measure frailty changes. The study will gather neurological and muscular phenotyping data to track participants health trajectories. The study spans from baseline to a 6-month follow-up, monitoring physical and cognitive function to inform future clinical strategies for minimizing risks linked to aging and neurological disorders.

Researchers are evaluating a new rehabilitation process to assess and relieve chemotherapy-induced peripheral neuropathy in the feet of patients treated for early-stage breast cancer. This study compares two orthopedic supports a standard treatment using customized insoles and shoes, and a novel silicone orthosis designed as a soft, sock-like device for indoor use. The goal is to understand if the silicone orthosis can reduce symptoms and improve function compared to standard treatment. Participants will be randomly assigned to receive either the customized insoles and shoes or the silicone orthosis along with the standard treatment. The study involves initial assessments including symptom grading, foot health questionnaires, quality of life scales, and 3D foot scanning. Activity levels will be tracked using an activity sensor worn on the leg for two weeks. Participants using the silicone orthosis will keep a diary of device usage. Follow-ups occur 3 to 6 weeks after starting the intervention to evaluate symptom changes and patient experiences. During the study, participants will undergo foot examinations and complete questionnaires about their symptoms, foot health, and quality of life. Mobility and activity patterns will be monitored objectively with activity trackers. Follow-up may be conducted in person, by phone, or digitally, lasting about 45 minutes. The main outcomes include changes in neuropathy symptoms and physical activity after 3 to 6 weeks of using the orthopedic devices. This research aims to improve rehabilitation care for breast cancer survivors experiencing foot neuropathy from chemotherapy.

Researchers are evaluating the safety and effectiveness of a new limb cryocompression device called the Paxman Limb Cryocompression System PLCS in preventing chemotherapy-induced peripheral neuropathy in cancer patients. This study involves 200 cancer patients receiving weekly paclitaxel chemotherapy, aiming to develop a therapy that reduces nerve damage caused by chemotherapy. The trial is sponsored by the National University Hospital, Singapore, and includes participants aged 21 to 80 years. Participants will undergo limb cryocompression treatment during each chemotherapy cycle using cooling wraps that cover the limbs from the digits to the elbow or knee. The therapy involves 30 minutes of cooling before chemotherapy infusion, continued cooling during chemotherapy, and 30 minutes after infusion, totaling up to 4 hours per cycle. This cryocompression treatment is repeated for up to 12 cycles, with the possibility of extension after consultation with the principal investigator. Throughout the study, participants will be monitored for treatment-emergent adverse events using established criteria over a 4-month period and assessed for changes in neuropathy symptoms using a quality-of-life questionnaire over 16 months. Usability of the PLCS device will also be evaluated. Monitoring will include repeated safety and symptom assessments during and after cryocompression treatment, with the total study duration extending up to 16 months.

Researchers are studying the safety and effectiveness of a single dose of nexiguran ziclumeran NTLA-2001 compared to a placebo in people with hereditary transthyretin amyloidosis with polyneuropathy ATTRv-PN. This phase 3, multinational, randomized, double-blind, placebo-controlled trial involves about 60 participants with this nerve disease and genetic condition affecting the peripheral nervous system. Participants will be randomly assigned to receive a single intravenous infusion of either nexiguran ziclumeran 55 mg or a placebo of normal saline. To give everyone a chance to receive the study drug, participants may switch to the other treatment group at either 12 or 18 months, depending on specific study criteria. The study is designed to compare the effects of the drug and placebo over time. During the study, participants will be monitored for nerve function using the Modified Neuropathy Impairment Score 7 mNIS7 over 18 months and blood levels of serum transthyretin at 29 days and 18 months. Quality of life, body mass index, and other health measures will also be evaluated. The study includes careful safety monitoring and will last up to 18 months with ongoing assessments to track participants nerve health and overall well-being.

Researchers are evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of YOLT-201 in adults aged 18 to 80 with hereditary transthyretin amyloidosis affecting nerves polyneuropathy or the heart cardiomyopathy. This study focuses on participants with confirmed genetic mutations causing these conditions to better understand how YOLT-201 behaves and is tolerated in these groups. The study involves giving participants a single infusion of YOLT-201 and monitoring them over time. This is an open-label trial, so all participants receive the study drug without a placebo group. The study includes an initial dose-escalation phase followed by a dose-expansion phase to assess different dosing levels and effects. Participants will be closely monitored for safety and tolerability through week 104, with regular assessments including laboratory tests and clinical evaluations. Researchers will track how the drug is processed in the body and its biological effects. Participants agree to avoid certain treatments and follow contraceptive guidelines during the study. The total duration includes screening, treatment, and long-term follow-up to understand the drugs impact and safety profile.